⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8553557 | 0.83 | — | — | |
| SCHEMBL4922033 | 0.81 | — | — | |
| SCHEMBL1654683 | 0.79 | LMNA (0.36) | — | |
| SCHEMBL27026953 | 0.79 | — | — | |
| SCHEMBL28038843 | 0.78 | — | — | |
| SCHEMBL9405428 | 0.75 | — | — | |
| SCHEMBL7767282 | 0.74 | PTGS1 (0.39) | — | |
| SCHEMBL4373286 | 0.73 | — | — | |
| SCHEMBL14277005 | 0.73 | MEN1 (0.32) | — | |
| SCHEMBL42331 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025081019-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024137674-A2 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024105159-A1 | LIGANDS OF THE M6A-RNA READERS | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023212240-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022268230-A1 | COMPOUND AS KIF18A INHIBITOR | 杭州英创医药科技有限公司 | 2022-12-29 | — | — | WO | disclosed |
| EP-3795568-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3265456-B1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1311500-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016348-A1 | ANTIANGIOGENIC BICYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012227-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |